RSV M protein interacts with host cell membranes, holding together the virus’s filamentous structure and coordinating viral components and other proteins — including RSV F proteins.

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness, according to Yale research published in JAMA Network Open.

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance ...

Respiratory syncytial virus, or RSV, is a common virus that infects the nose, throat and lungs, according to the U.S. Centers for Disease Control and Prevention. Is it RSV, COVID or the flu?

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated lower respiratory tract illness in people aged ≥ 60 years.

Analysis of 472 RSV-A samples (half from treated children) revealed no nirsevimab resistance mutations in the F protein epitope site. Among the 73 children infected with RSV-B, 24 had received ...

However, the uptake of the RSV vaccine in the 2023-2024 winter season was low. An estimated 24 percent of US adults aged 60 years and older received the vaccine, compared to influenza vaccination ...